Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy.
Fortin Ensign SP, Gaulin C, Hrachova M, Ruff M, Harahsheh E, Vicenti K, Castro J, Munoz J, Rosenthal A, Mrugala MM. Fortin Ensign SP, et al. Among authors: ruff m. Curr Treat Options Oncol. 2022 Dec;23(12):1845-1860. doi: 10.1007/s11864-022-01035-2. Epub 2022 Dec 16. Curr Treat Options Oncol. 2022. PMID: 36525238 Review.
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, Manriquez Roman C, Hansen MJ, Tapper EE, Siegler EL, Forsman C, Crotts SB, Schick KJ, Hefazi M, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Nevala WK, Braggio E, Ding W, Parikh SA, Kay NE, Kenderian SS. Cox MJ, et al. Among authors: ruff mw. Mol Ther. 2021 Apr 7;29(4):1529-1540. doi: 10.1016/j.ymthe.2020.12.033. Epub 2021 Jan 1. Mol Ther. 2021. PMID: 33388419 Free PMC article.
Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Sakemura R, Bansal A, Siegler EL, Hefazi M, Yang N, Khadka RH, Newsom AN, Hansen MJ, Cox MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Nevala WK, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Horvei P, Ruff MW, Parikh SA, Pandey MK, DeGrado TR, Suksanpaisan L, Kay NE, Peng KW, Russell SJ, Kenderian SS. Sakemura R, et al. Among authors: ruff mw. Cancer Immunol Res. 2021 Sep;9(9):1035-1046. doi: 10.1158/2326-6066.CIR-20-0901. Epub 2021 Jul 8. Cancer Immunol Res. 2021. PMID: 34244299 Free PMC article.
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.
Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, Lin Y, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Sakemura R, et al. Among authors: ruff mw. Blood. 2022 Jun 30;139(26):3708-3721. doi: 10.1182/blood.2021012811. Blood. 2022. PMID: 35090171 Free PMC article.
Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).
Saw JL, Sidiqi MH, Ruff M, Hocker S, Alkhateeb H, Ansell SM, Bennani NN, Dingli D, Hayman SR, Johnston PB, Kapoor P, Kenderian SJ, Kourelis TV, Kumar SK, Paludo J, Shah MV, Siddiqui MA, Warsame R, Rosenthal A, Grill M, Castro JE, Siegel J, Abdel Rahman ZH, Kharfan-Dabaja MA, So E, Lin Y. Saw JL, et al. Among authors: ruff m. Blood Cancer J. 2022 Apr 13;12(4):62. doi: 10.1038/s41408-022-00657-x. Blood Cancer J. 2022. PMID: 35418113 Free PMC article. No abstract available.
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.
Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, Paludo J, Villasboas JC, Dingli D, Kourelis T, Leung N, Alkhateeb H, Ruff MW, Gallo de Moraes A, Vergidis P, Herrmann J, Kenderian SS, Bennani NN, Johnston PB, Ansell SM, Lin Y. Khurana A, et al. Among authors: ruff mw. Blood Cancer J. 2024 Aug 12;14(1):136. doi: 10.1038/s41408-024-01119-2. Blood Cancer J. 2024. PMID: 39134524 Free PMC article. No abstract available.
Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.
Vora S, Pafundi D, Voss M, Buras M, Ashman J, Bendok B, Breen W, Hu L, Kizilbash S, Laack N, Liu W, Mahajan A, Mrugala M, Porter A, Ruff M, Sio T, Uhm J, Yang M, Brinkmann D, Brown P. Vora S, et al. Among authors: ruff m. Lancet Oncol. 2024 Dec;25(12):1625-1634. doi: 10.1016/S1470-2045(24)00585-0. Epub 2024 Nov 18. Lancet Oncol. 2024. PMID: 39571596 Clinical Trial.
368 results